Snapshot from Aug 07, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Immix Biopharma CMO Fraud Investigation
Regulatory securities fraud

Immix Biopharma CMO Fraud Investigation

Analysis based on 6 articles · First reported Jul 30, 2026 · Last updated Aug 07, 2026

Sentiment
-30
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The revelation that GT Biopharma's former CMO was a fugitive and the subsequent investigation have negatively impacted investor confidence, leading to a significant drop in the company's stock price. The ongoing investigation may result in legal liabilities, regulatory penalties, and further reputational damage, potentially affecting the company's market valuation and access to capital.

Biotechnology Pharmaceuticals
Event Summary

GT Biopharma, Inc. (NASDAQ: IMMX) is under investigation by Pomerantz LLP for potential securities fraud and unlawful business practices. The investigation stems from the company's appointment of Richard Graydon as Chief Medical Officer in March 2026 and his subsequent termination on July 17, 2026. Media reports, citing the U.S. Marshals Service, revealed that Graydon's real identity was Ronald L. Fischer, a fugitive who had disappeared during his 2005 rape trial and spent over 20 years evading law enforcement until his arrest in July 2026. Following the news of Graydon's true identity and termination, Immix's stock price fell 14.15% to $8.80 per share on July 20, 2026. Pomerantz LLP is investigating whether Immix and certain officers/directors engaged in securities fraud or other unlawful practices related to these events.

Key Actions
80 Pomerantz LLP investigating claims GT Biopharma
70 GT Biopharma terminated employment Richard Graydon
60 United States — United States Marshals Service arrested fugitive Ronald L. Fischer
Entities Involved
stock
GT Biopharma
GT Biopharma is the subject of the investigation and experienced a 14.15% stock price decline following the disclosure of its former CMO's fugitive status. The company faces potential legal and regulatory consequences that could harm its financial position and reputation.
Importance 100.0 Sentiment -40.0
per
Richard Graydon
Richard Graydon, the alias used by Ronald L. Fischer, was appointed as CMO and later terminated. His fraudulent identity and criminal background have severely damaged Immix's credibility and triggered the investigation.
Importance 80.0 Sentiment -50.0
per
Ronald L. Fischer
Ronald L. Fischer, the real identity of Richard Graydon, is a fugitive who was arrested after 20 years. His arrest and exposure have directly caused the negative market reaction and legal scrutiny on Immix.
Importance 80.0 Sentiment -50.0
priv
Pomerantz LLP
Pomerantz LLP is conducting the investigation on behalf of investors, positioning itself as a legal advocate. The firm's involvement may lead to class action litigation against Immix, potentially resulting in financial recoveries for affected investors.
Importance 70.0 Sentiment 0.0
govactor
United States — United States Marshals Service
The U.S. Marshals Service arrested Ronald L. Fischer, providing the information that exposed the fraud. Their role is central to the event but they are not directly affected financially.
Importance 60.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.